AffyImmune Therapeutics
Newton
About AffyImmune Therapeutics
AffyImmune Therapeutics is a biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor (“CAR”) T cell therapy in solid tumors. The Company’s proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down the affinity from picomolar to micromolar level to lower the on-target off-tumor toxicity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $28.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2021)
- Website: affyimmune.com
- Phone: (617) 699-1965
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/affyimmune-therapeutics-3981 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.